Clinical Trial Update: FOLFOX6 Versus mFOLFIRINOX as First Line Chemotherapy in Metastatic Gastric Cancer or Esophagogastric Junction Adenocarcinoma (Type II-III) [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial comparing FOLFOX6 vs mFOLFIRINOX as first-line chemotherapy in metastatic gastric cancer or esophagogastric junction adenocarcinoma (Ty…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophagogastric Junction Adenocarcinoma
• Gastric Carcinoma

Drugs mentioned

• FOLFOX6
• mFOLFIRINOX

Snippet

Sponsor: Blokhin's Russian Cancer Research Center | Conditions: Gastric Carcinoma Stage IV, Esophagogastric Junction Adenocarcinoma Stage IV | Phase 2 | Status: UNKNOWN